NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Onconetix, Inc. (ONCO) Stock Analysis

Onconetix, Inc. (ONCO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ONCO

$0.44

+$0.03 (+7.09%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ONCO with… →

ONCO Key Statistics

As of Oct 21, 2026
Trading
Open
$0.43
Previous Close
$0.41
Day's Range
0.41–0.46
52-Week Range
0.38–200.00
Volume
676.92K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.61
Valuation
Market Cap
$2.28M
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.53
Financials (FY)
Revenue (FY)
$815.37K−67.70%
Net Income (FY)
−$14.03M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.24M
1-Year Return
−99.76%
Dividend and dates
Avg Volume
2.91M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ONCO closed at $0.44, −99.76% over 1 year.

Onconetix, Inc. (ONCO) has a market capitalization of $2.28M.

In fiscal 2025, ONCO reported revenue of $815.37K.

ONCO Stock Return by Calendar Year

Onconetix, Inc. (ONCO) return since Feb 2022: what $10,000 became

1 year
$10,000 $24
−99.76%
3 years
$10,000 $0.06
−99.999%
Since Feb 2022
$10,000 $0.0004
−99.999996%

If you had invested $10,000 in Onconetix, Inc. (ONCO) at the close on February 18, 2022, the earliest close on record here, it would have been worth $0.0004 at the close on October 21, 2026: −99.999996% in total, −97.33% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−99.44%
2025−97.09%
2024−92.05%
2023−82.00%
2022 (partial year)−98.08%

As of October 21, 2026.

ONCO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$815.37K−$14.03M−1,721.0%
2024$2.52M−$58.69M−2,325.2%
2023$58.47K−$37.41M−63,986.5%
2022$0.00−$13.42M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$815.37K$632.91K−$6.34M−$14.03M−1,721.0%
2024$2.52M$1.06M−$10.33M−$58.69M−2,325.2%
2023$58.47K−$1.13M−$17.85M−$37.41M−63,986.5%
2022$0.00$0.00−$13.48M−$13.42M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ONCO Valuation vs Biotechnology Median

Median of 608 stocks
MetricONCOBiotechnology medianvs median
P/S ratio3.5313.300.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Onconetix, Inc. (ONCO) at $2.28M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2.

Over the past 52 weeks the price has ranged from $0.38 to $200.00. The most recent close on file for ONCO is $0.44, dated October 21, 2026. That is +$0.03 (+7.09%) against the previous close. The latest close sits 14.53% above that 52-week low.

Financial Health

In fiscal 2025, Onconetix, Inc. reported revenue of $815.37K. Against the prior fiscal year total of $2.52M, that is a change of −67.70%. The same year closed with a net loss of $14.03M.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $815.37K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The price-to-sales ratio is 3.53. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −99.76%. Measured over 3 years, that is −98.16% a year compounded. The reported beta is 2.61. Daily returns over the trailing 4 years annualize to a volatility of 163.92%.

Growth & Income

The record shows no dividend for ONCO.

Across the complete calendar years on file, 2023 returned −82.00% and 2025 returned −97.09%. Of the 3 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −99.44% year to date.

Peer Comparison

Onconetix, Inc. (ONCO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Onconetix, Inc. ONCO $2.28M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Onconetix, Inc.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Visit website →